-- 根據週二提交給香港交易所的文件顯示，GenFleet Therapeutics（上海）有限公司（港交所代碼：2595）表示，Revolution Medicines就RAS抑制劑相關的專利和商業秘密糾紛發出的信函與該公司無關。 GenFleet表示，信函中提及的所有實體、產品和爭議事項均與該公司「完全無關」。 該公司補充道，GFH276是基於完全獨立、原創且專有的智慧財產權開發的，因此不存在此類風險。 該公司表示，已為其泛RAS抑制劑計畫建構了全球專利組合，其中GFH276化合物結構的核心專利已於2025年3月6日公佈，預計保護期至2044年。 GenFleet股價在近期交易下跌近7%。
Related Articles
Research
Morgan Stanley Upgrades Garmin to Equalweight From Underweight, Adjusts PT to $252 From $195
Garmin (GRMN) has an average rating of hold and mean price target of $261.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GRMN
Research
Morgan Stanley Upgrades Phillips 66 to Overweight From Equalweight, Adjusts PT to $174 From $147
Phillips 66 (PSX) has an average rating of overweight and mean price target of $182.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$PSX
Research
Morgan Stanley Downgrades CSX to Underweight From Equalweight, Price Target is $30
CSX (CSX) has an average rating of overweight and mean price target of $45.84, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$CSX